Autres langues I-Mab Deutsche Boerse AG

Actions

0VY

US44975P1030

Temps réel estimé Tradegate Autres places de cotation 21:13:34 27/06/2024			Varia. 5j.	Varia. 1 janv.
1,565 ^EUR	-1,57%		-1,26%	-4,85%

06/06	I-Mab nomme Phillip Dennis au poste de directeur médical	CI
05/06	I-Mab collabore avec Bristol-Myers pour évaluer le givastomig dans une étude de combinaison pour les cancers de l'estomac et de l'œsophage	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	07/06
I-Mab Appoints Phillip Dennis as Chief Medical Officer	06/06
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05/06
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	23/05
I-Mab to Participate at the Jefferies Global Healthcare Conference	22/05
I-MAB Filed 2023 Annual Report on Form 20-F	30/04
Verastem Names John Hayslip as Chief Medical Officer	18/04
I-Mab Announces Chief Medical Officer Changes	15/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	08/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	05/04
I-Mab Completes Business Divestiture in China	02/04
I-Mab Announces Closing of the Divestiture of Business Operations in China	02/04
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04
I Mab : Resignations of Director and Senior Management - Form 6-K	01/04
I-Mab Announces Executive Resignation	01/04
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
I-Mab Divests China Operations, Shifts Focus to US Market	09/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues I-Mab Deutsche Boerse AG

Actions

0VY

US44975P1030

Autres langues

Filtres